Free Trial
NASDAQ:ACHV

Achieve Life Sciences (ACHV) Stock Price, News & Analysis

Achieve Life Sciences logo
$2.78 -0.12 (-4.14%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$2.78 0.00 (-0.18%)
As of 03/28/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Achieve Life Sciences Stock (NASDAQ:ACHV)

Key Stats

Today's Range
$2.74
$2.89
50-Day Range
$2.65
$3.53
52-Week Range
$2.51
$5.59
Volume
116,368 shs
Average Volume
174,603 shs
Market Capitalization
$96.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.75
Consensus Rating
Buy

Company Overview

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.

Remove Ads

Achieve Life Sciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
40th Percentile Overall Score

ACHV MarketRank™: 

Achieve Life Sciences scored higher than 40% of companies evaluated by MarketBeat, and ranked 744th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Achieve Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.40, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Achieve Life Sciences has received no research coverage in the past 90 days.

  • Read more about Achieve Life Sciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Achieve Life Sciences are expected to grow in the coming year, from ($1.17) to ($1.16) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Achieve Life Sciences is -2.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Achieve Life Sciences is -2.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Achieve Life Sciences' valuation and earnings.
  • Percentage of Shares Shorted

    8.99% of the float of Achieve Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Achieve Life Sciences has a short interest ratio ("days to cover") of 12.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Achieve Life Sciences has recently decreased by 3.81%, indicating that investor sentiment is improving.
  • Dividend Yield

    Achieve Life Sciences does not currently pay a dividend.

  • Dividend Growth

    Achieve Life Sciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.99% of the float of Achieve Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Achieve Life Sciences has a short interest ratio ("days to cover") of 12.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Achieve Life Sciences has recently decreased by 3.81%, indicating that investor sentiment is improving.
  • News Sentiment

    Achieve Life Sciences has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Achieve Life Sciences this week, compared to 2 articles on an average week.
  • Search Interest

    Only 5 people have searched for ACHV on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Achieve Life Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $28,900.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 2.00% of the stock of Achieve Life Sciences is held by insiders.

  • Percentage Held by Institutions

    Only 33.52% of the stock of Achieve Life Sciences is held by institutions.

  • Read more about Achieve Life Sciences' insider trading history.
Receive ACHV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achieve Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

ACHV Stock News Headlines

Alert: DOGE goes live
Elon will most likely be at the helm of it all. And just days from now, could bring about the biggest economic transformation in American history. See, there's one particular part of Elon and Trump's plans that you need to pay special attention to right now.
Achieve Life Sciences, Inc. (ACHV): A Bull Case Theory
ACHV: 2Q:25 NDA Submission
Lake Street Keeps Their Buy Rating on Achieve Life Sciences (ACHV)
See More Headlines

ACHV Stock Analysis - Frequently Asked Questions

Achieve Life Sciences' stock was trading at $3.52 on January 1st, 2025. Since then, ACHV shares have decreased by 21.0% and is now trading at $2.78.
View the best growth stocks for 2025 here
.

Achieve Life Sciences, Inc. (NASDAQ:ACHV) issued its earnings results on Tuesday, March, 11th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by $0.06.

Achieve Life Sciences shares reverse split on Friday, July 31st 2020. The 1-20 reverse split was announced on Thursday, July 30th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Achieve Life Sciences' top institutional investors include Franklin Resources Inc. (11.20%), Geode Capital Management LLC (2.20%), Alyeska Investment Group L.P. (1.22%) and Northern Trust Corp (1.21%). Insiders that own company stock include John Bencich and Mark K Oki.
View institutional ownership trends
.

Shares of ACHV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Achieve Life Sciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Meta Platforms (META), Moderna (MRNA), Netflix (NFLX) and Visa (V).

Company Calendar

Last Earnings
3/11/2025
Today
3/30/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ACHV
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.75
High Stock Price Target
$20.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+466.5%
Consensus Rating
Buy
Rating Score (0-4)
3.40
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-29,820,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($0.07) per share
Price / Book
-39.71

Miscellaneous

Free Float
33,702,000
Market Cap
$96.42 million
Optionable
Optionable
Beta
1.67

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

Get This Free Report

This page (NASDAQ:ACHV) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners